1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
21 |
22 |
23 |
24 |
25 |
26 |
27 |
28 |
29 |
30 |
31 |
32 |
33 |
34 |
35 |
36 |
37 |
38 |
39 |
40 |
41 |
42 |
43 |
44 |
45 |
46 |
47 |
48 |
49 |
50 |
51 |
52 |
53 |
54 |
55 |
VectivBio Earns FDA Orphan Drug Designation for Apraglutide
Release Date: 07 September 2021
US FDA has allowed orphan drug designation to apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases, for the prevention of acute graft-versus-host disease (aGVHD). Gastrointestin...
Read More
CPI-613® (Devimistat) Receives Orphan Drug Designation From U.S FDA
Release Date: 06 September 2021
US FDA grants Orphan Drug Designation to CPI-613andreg; (devimistat) for the treatment of biliary cancer. The EMA has granted orphan drug designation to devimistat for acute myeloid leukemia and pancreatic cancer. Biliary cancer that inc...
Read More
Atsena Therapeutics Earns Orphan Drug Designation from US FDA for Novel Gene Therapy
Release Date: 06 September 2021
US FDA has granted orphan drug designation for its investigational gene therapy product for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina. Efficacy and safety of the g...
Read More
US FDA Grants Orphan Drug Designation For Xywav
Release Date: 05 September 2021
US FDA has granted Orphan Drug Designation for Xywavandtrade; (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older wi...
Read More
BNL-101 Wins Orphan Drug Designation To Treat Malignant Gliomas
Release Date: 05 September 2021
Bionaut Labs, a company has been grated the orphan drug designation from FDA to BNL-101 for the treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients. BNL-101 is a drug-device combi...
Read More
US FDA Grants Orphan Drug Designation for GS-100 Drug
Release Date: 04 September 2021
Grace Science receives orphan drug designation from FDA for GS-100, an investigational AAV9 gene replacement therapy to treat NGLY1 deficiency. NGLY1 deficiency is an ultra-rare genetic disease caused by loss of function mutations in the...
Read More
EMA Grants Orphan Drug Designation to CLN5 Batten Disease Gene Therapy
Release Date: 04 September 2021
Neurogene Inc., a company receives Orphan Drug Designation from European Medicines Agency (EMA) to its adeno-associated virus (AAV) encoding a codon-optimized human CLN5 transgene (hCLN5) to treat CLN5, a subtype of Batten disease. Sympt...
Read More
EMA Grants Orphan Drug Designation To SLS-005
Release Date: 03 September 2021
Seelos Therapeutics receives orphan drug designation from The European Medicines Agency (EMA) for SLS-005 for the treatment of amyotrophic lateral sclerosis (ALS). In ALS, the accumulation of proteins such as TDP-43 and SOD1 in nerve cel...
Read More
PT001 Receives Orphan Drug Designation To Treat Pulmonary Arterial Hypertension
Release Date: 03 September 2021
PulmoSIM Therapeutics receives Orphan Drug Designation from US FDA for PT001 for the treatment of Pulmonary Arterial Hypertension (PAH). PAH is a disturbing, progressive and life-threatening disorder characterized by increased pressure i...
Read More
FDA Approve Peptide Drug Conjugate Antibody To Witness Positive Outlook In Future
Release Date: 17 April 2021
Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:
-
First FDA Approved Peptide Drug Conjugate: Pepaxto (Mel...
Read More
United States US Cancer Antibodies Market USD 70 Billion Opportunity
Release Date: 12 April 2021
"US Cancer Antibody Market, Drug Price, Sales and Clinical Trials Insight 2026" Report Highlights:
-
US Cancer Antibodies Market Opportunity...
Read More
Global Peptide Cancer Market USD 20 Billion Opportunity 2026
Release Date: 12 April 2021
"Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:
-
Global cancer Peptide Market...
Read More
Angiotensin II Receptor Blocker Drug to Boost the Potential of PD-1 Inhibitor Immunotherapy
Release Date: 23 December 2020
A novel study indicates that a class of drugs could patiently improve the response of the patients towards some of the anti-cancer immunotherapy drugs such as PD-L1 inhibitors. According to the researchers working on the clinical research study, Angiotensin II blocke...
Read More
Novel Research Study Inclined towards Ending SARS-CoV-2 Pandemic
Release Date: 06 December 2020
Since the pandemic, thousands of researchers across the globe are focused towards finding an efficient therapy for Covid-19. A novel study focused towards Covid-19 states that synthetic nanobodies or sybodies could play very important ro...
Read More
Role of Weight Loss Surgery in Tpe-2 Diabetes
Release Date: 30 November 2020
Researchers from British Obesity and Metabolic Surgery Society (BOMSS) and the Population Health Research Institute at St Georges revealed that weight loss surgery can put severe form of diabetes-2 into remission. For this study, p...
Read More
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |